Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | Chief Scientific Officer | August 10, 2021 | August 12, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulcrum Therapeutics, Inc.
Report date August 10, 2021 · Filed August 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,071 |
Ending reported balance
After 2021-08-10 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-08-10 · Exercise / conversion · Acquired 20,714 · Balance 20,714 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2020. Row 2 · 2021-08-10 · Sale · Disposed 20,714 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2020. Row 3 · 2021-08-10 · Exercise / conversion · Acquired 31,071 · Balance 31,071 F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2021. |
| Common StockmSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-08-10 transaction · row 4
1 source rowRow 4 · 2021-08-10 · Sale · Disposed 31,071 · Balance 0 F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.84 · Expires 2029-01-21 | Direct | 103,572 |
Reported balance
After 2021-08-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-08-10 · Exercise / conversion · Disposed 20,714 · Balance 103,572 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2020. F3: The shares underlying the option are scheduled to vest 25% on the first anniversary of the vesting commencement date of January 22, 2020. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.84 · Expires 2029-01-21 | Direct | 72,501 |
Reported balance
After 2021-08-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-08-10 · Exercise / conversion · Disposed 31,071 · Balance 72,501 F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2021. F3: The shares underlying the option are scheduled to vest 25% on the first anniversary of the vesting commencement date of January 22, 2020. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2020.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2021.
F3: The shares underlying the option are scheduled to vest 25% on the first anniversary of the vesting commencement date of January 22, 2020. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2021 Filed Aug 12, 2021 20:20 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock Option (right to buy) · Derivative | 31,071 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0000899243-21-032755 · doc4.xml · derivative · entry 6 Moxham Christopher · CIK 0001843784 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,501 Underlying: Common Stock · 31,071 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2021. F3 · derivative.exercise_date: The shares underlying the option are scheduled to vest 25% on the first anniversary of the vesting commencement date of January 22, 2020. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 20:20 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock Option (right to buy) · Derivative | 20,714 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0000899243-21-032755 · doc4.xml · derivative · entry 5 Moxham Christopher · CIK 0001843784 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,572 Underlying: Common Stock · 20,714 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2020. F3 · derivative.exercise_date: The shares underlying the option are scheduled to vest 25% on the first anniversary of the vesting commencement date of January 22, 2020. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 20:20 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stockm | 31,071 | $18.00 | $559,278.00 |
DisclosureSEC source: 0000899243-21-032755 · doc4.xml · nonDerivative · entry 4 Moxham Christopher · CIK 0001843784 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2021. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 20:20 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 31,071 | $7.84 | $243,596.64 |
DisclosureSEC source: 0000899243-21-032755 · doc4.xml · nonDerivative · entry 3 Moxham Christopher · CIK 0001843784 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2021. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 20:20 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 20,714 | $17.00 | $352,138.00 |
DisclosureSEC source: 0000899243-21-032755 · doc4.xml · nonDerivative · entry 2 Moxham Christopher · CIK 0001843784 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2020. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 20:20 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 20,714 | $7.84 | $162,397.76 |
DisclosureSEC source: 0000899243-21-032755 · doc4.xml · nonDerivative · entry 1 Moxham Christopher · CIK 0001843784 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2020. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:30 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $12.60 | $0.00 |
DisclosureSEC source: 0000899243-21-005666 · doc4.xml · derivative · entry 1 Moxham Christopher · CIK 0001843784 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-02-07 F1 · derivative.exercise_date: This option was granted on February 8, 2021 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of February 6, 2021, subject to continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.